Arthneeti
All Q2 FY26 results →
Z.

Zoetis Inc.

Q2 FY26Pharmaceuticals

Zoetis Inc. Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹78
Market cap₹32.8K Cr
P/E13.2
Updated29 May 2026
Read3 min read

What the Q2 FY26 call signalled

1 of 4 strong

RevenueSlow growth
MarginMargins steady
CapexCapex planned
Order bookOrder book flat

The short version

- Zoetis projects full-year 2026 revenue growth of 2% to 5% based on the current operating environment. - Zoetis updated full-year 2026 revenue guidance to $9.68 billion - $9.96 billion, representing 2% to 5% growth, reflecting current operating environment with macro and competitive challenges.

From Zoetis Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Slow growth
  • Zoetis projects full-year 2026 revenue growth of 2% to 5% based on the current operating environment.
  • Livestock segment expected to drive momentum with mid- to high single-digit growth for the year.
  • Companion animal growth anticipated but at a slower pace than livestock; international companion animal sales grew 7% this quarter.
  • The company is focused on expanding markets to counteract competitive and macroeconomic pressures, particularly in parasiticides and OA Pain areas.
  • Expected challenges include ongoing macroeconomic price sensitivity, competitive intensity, and lower vet clinic visit volumes.

2 more points from Zoetis Inc.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Zoetis Inc. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Zoetis is actively investing in its business and innovation pipeline as a priority for capital allocation.
  • The company announced an agreement to acquire Neogen’s animal genomics business, expanding capabilities in livestock genetics—reflecting a targeted, strategic business development approach.
  • Investment focus includes scaling innovation, shortening time from approval to launch, and advancing convenience-led life cycle innovations (e.g., long-acting mAbs, Procerta, Convenia RTU).
  • There is an emphasis on driving procurement and operating efficiencies as part of a comprehensive cost and productivity program.

2 more points from Zoetis Inc.'s call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Zoetis Inc. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book flat
The discussion primarily revolves around: - Financial performance and revenue details for Q1 2026. - Impact of macroeconomic factors, competitive landscape, and consumer price sensitivity. - Guidance updates reflecting these market conditions. - Sales mix and geographic effects on revenue and margins.

2 more points from Zoetis Inc.'s call on order book

Create a free account to keep reading this call

Continue your research

Others in Pharmaceuticals this season

  • Elanco Animal Health Incorporated (Q2 FY26)

    Elanco Animal Health Incorporated Q2 FY26 quarterly results analysis. Elanco expects continued momentum with high single-digit to low double-digit growth in U.S

  • Axsome Therapeutics, Inc. (Q2 FY26)

    Axsome Therapeutics, Inc. Q2 FY26 quarterly results analysis. AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from

  • Jazz Pharmaceuticals plc (Q2 FY26)

    Jazz Pharmaceuticals plc Q2 FY26 quarterly results analysis. Epidiolex: Encouraged by strong first-quarter performance ($250 million; 15% revenue growth, 16% vo

  • Viatris Inc. (Q2 FY26)

    Viatris Inc. Q2 FY26 quarterly results analysis. Viatris aims for 4% organic revenue growth by 2030, starting strong with 3% growth in Q1 2026. Market Cap $18,7

Compare:vs AstraZeneca PLCvs Johnson & Johnsonvs Novartis AG

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Zoetis Inc. and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Zoetis Inc. Q2 FY26 results?

- Zoetis projects full-year 2026 revenue growth of 2% to 5% based on the current operating environment. - Zoetis updated full-year 2026 revenue guidance to $9.68 billion - $9.96 billion, representing 2% to 5% growth, reflecting current operating environment with macro and competitive challenges.

What is Zoetis Inc. share price analysis?

Zoetis Inc. currently shows a neutral. The stock trades at a P/E of 13.2 with a market cap of $32,813. Investors should review the full earnings analysis for detailed insights.

Is Zoetis Inc. planning capital expenditure?

- Zoetis is actively investing in its business and innovation pipeline as a priority for capital allocation.

Keep Zoetis Inc. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.